Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. - Wikidata - awgldk - TriplyDB

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

http://www.wikidata.org/entity/Q36516888

about

Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts Recent advances in understanding idiopathic pulmonary fibrosis Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis.Genome-wide DNA methylation analysis in lung fibroblasts co-cultured with silica-exposed alveolar macrophages.Glucose Transporter 1-Dependent Glycolysis Is Increased during Aging-Related Lung Fibrosis, and Phloretin Inhibits Lung Fibrosis.Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis.Involvement of the Warburg effect in non-tumor diseases processes.PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways.Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies?Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.In vivo imaging of the progression of acute lung injury using hyperpolarized [1-13 C] pyruvate.Targeting HIF-1α/PDK1 Axis by Dichloroacetate (DCA) Suppresses Bleomycin-induced Pulmonary Fibrosis.Towards a global initiative for fibrosis treatment (GIFT).Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process.Glutaminolysis is required for TGF-β1-induced myofibroblast differentiation and activation.Inhibition of PHGDH Attenuates Bleomycin-induced Pulmonary Fibrosis.Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis.Targeting metabolic abnormalities to reverse fibrosis in iatrogenic laryngotracheal stenosis.Metabolic characterization and RNA profiling reveal glycolytic dependence of profibrotic phenotype of alveolar macrophages in lung fibrosis.Mitochondrial Dysfunction in Pulmonary Fibrosis.Metabolic Disorders in Chronic Lung Diseases.Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics.Metabolic reprogramming in the pathogenesis of chronic lung diseases including BPD, COPD, and pulmonary fibrosis.Glutaminolysis Promotes Collagen Translation and Stability via α-ketoglutarate Mediated mTOR Activation and Proline Hydroxylation.The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Radiation-Induced Pulmonary Fibrosis.Metabolic variations in normal and fibrotic human laryngotracheal-derived fibroblasts: A Warburg-like effect.Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production.Dealing with Stress: Defective Metabolic Adaptation in Chronic Obstructive Pulmonary Disease Pathogenesis.Fibrosis: Lessons from OMICS analyses of the human lung.The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis.Fatty acid synthase is required for profibrotic TGF-β signaling.Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis.Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol.PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway Fructose 2,6-Bisphosphate in Cancer Cell Metabolism

P2860

Q26745566-00452D3E-9B80-416D-A75A-42446D733600 Q26745905-B058BFC7-B14D-48CC-A99B-3AAB7DCBDE9A Q28267012-69025565-035C-4BF6-BDAB-DB52EEEE834F Q33612767-FB2730F2-7142-4FE0-9661-9C89D6B5AF84 Q33677179-56CF94C8-8BDC-494D-8927-ADF8E3E06E91 Q38407419-4AA8021A-B5FD-4826-B531-E7ED69672F98 Q38913044-DB6A16D6-E402-4EEA-860D-52835D49E96D Q39295263-909A0C59-C08E-4DCB-81F1-AD79FAF88DBF Q40561376-0FDC6B51-F610-4B8C-A76C-35E92367897D Q42705478-55A3EB66-6ABE-494C-BC8F-5707B93EEECC Q43062781-1E4ECEDF-E217-4D72-AF13-1C0361215C41 Q45968248-74555048-07CC-4C60-9442-EEE8F8B3494C Q46121598-61F71680-2FAB-4434-8996-8E4803E242B3 Q46792366-1AD8A38C-85B9-45B6-849A-3DF7A6ED4E2E Q47152449-82DE843E-D831-4CE1-A195-771D24AA2481 Q47282821-7D96B417-F4DB-48A8-A693-258E1F618F9E Q47313541-AA69389E-601F-4EEB-A9A6-E658226C6EB6 Q47667533-F5A2D1E9-C65E-40F9-A18A-20C7B0DCDA3C Q47699997-312618F7-8702-4251-A3B6-6420C4E3D421 Q47756863-BF01B252-8516-47CB-BA1B-04361C43B089 Q47804954-AA805EDB-D202-4001-A868-DD74E262DA06 Q48261825-9FC351C1-6A30-476C-9B6E-95148EC8F4A4 Q49795481-959E3B86-F1EF-47CC-90FE-6B1A6ED995D6 Q49828907-D5D9823B-3BF9-4B3F-B2D5-1BEEB0368A9B Q49918024-7C1B4E64-A6CB-46D6-A437-C8A48BF9EDCE Q50093331-10B1966E-79B3-4159-863E-21E35556E0F2 Q50649259-EBCD374B-CD52-4ED3-8F7D-B11F6040E048 Q51175912-45755E32-694E-447F-934D-F6DAE3981C7A Q51331227-18924DD5-E247-4D7A-8DC9-7336DA674B48 Q51760160-076C7388-4BB9-47C8-8C4B-5B0DCE09A10D Q51760494-278E0A72-7B71-456E-B3DB-F175A4C1FDC9 Q52332667-4996C6FC-5E4F-4BC8-AAEA-D778A1A565FB Q52373813-9688EBCC-D16B-4D2E-9763-C3C37AAF4F8C Q52578942-4660A5BC-E199-4006-8EDA-98344DD7C2CC Q55029093-F2B1F7ED-65A4-4A7A-A196-E2EE82EBDC0A Q58567411-D72B463D-D65F-4E80-A7F5-720D1E900646 Q58705752-15A761CA-40FB-4C36-AA72-9B4B1322EDA4 Q58764753-3F045EA1-2E4A-4747-80EA-F0CB23BEA8C0

P2860

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

http://www.wikidata.org/entity/Q36516888

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@ast

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@en

type

label

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@ast

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@en

prefLabel

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@ast

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@en

P1433

Q36516888-6A588C5C-3A4A-4FAB-AC9F-C816734E6227

P1476

Q36516888-3CBF6395-A781-4EDE-8C62-2B2BC6E9B6A9

P2093

Q36516888-173FEE88-9B48-4B65-BE76-C317D1A863DC

Q36516888-236569BE-9E05-4DA7-ADB9-8E5D18E56ACF

Q36516888-54117869-07F2-421F-B3D3-F49A8B10E29C

Q36516888-9F2EDFF6-E280-4B5A-88A5-C4370D3541F8

Q36516888-A60A31AF-6C4F-4E3E-BA71-D4E78C5CAB15

Q36516888-AB0BC33F-E6EA-4F36-A12F-D70BC19FDDBE

Q36516888-B1C6D770-0A00-4C1A-A1D9-23241D1FD8FE

Q36516888-D01C80DF-6383-4C3C-8B30-1BE67F3B96F6

Q36516888-FD86E066-D430-435B-AD7B-6C172FDEF242

P2860

Q36516888-059278D5-3411-4903-BC28-9D1CD2924073

Q36516888-06CE641A-74E3-46F9-9ECB-0514251D29E5

Q36516888-092B4475-2BF1-4DF2-AFD2-CBD0C221ADBD

Q36516888-15A6CE01-76F7-4F62-A7B4-65ED5F88AAA8

Q36516888-16198421-A386-47CD-8E3E-F9785AE22FA4

Q36516888-177BBC18-ED2B-4194-A362-2A949293B58A

Q36516888-1AA89136-21C4-4ED2-8234-46137423C648

Q36516888-1CB9EF79-4ABD-47F7-9A1F-5E5BAB52C795

Q36516888-1DB90801-339A-4062-87CB-4123DCFA2544

Q36516888-28BD7167-8C49-41D9-B8B5-F5146E9B743C

P304

Q36516888-96C5DA10-E3EE-47A0-8176-8FDCCC717F64

P31

Q36516888-C8F1C5C7-0200-4D74-8774-8469CDF710F5

P356

Q36516888-93298FDE-7C66-4872-825B-9F06BF52682B

P407

Q36516888-CD5AA3E4-C8CA-4AF6-837D-4C5E70B58A28

P433

Q36516888-773E649B-3D03-41DC-808A-D4E205C977EB

P478

Q36516888-63A4A419-45F5-4DC4-8990-11AFD576D97B

P577

Q36516888-8AE2678E-FF62-4E6D-B1D1-F44A77FDCF56

P698

Q36516888-3C5AC8FE-745D-4960-A349-18D9FD6A4449

P921

Q36516888-E3927C98-0B42-448F-BEBB-B4847C3F99F0

P932

Q36516888-DBB56257-BF6E-4B58-B411-45B1F52CB5F1

P356

RCCM.201504-0780OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

@en

P2093

Gang Liu

http://www.w3.org/2001/XMLSchema#string

Huachun Cui

http://www.w3.org/2001/XMLSchema#string

Jing Ge

http://www.w3.org/2001/XMLSchema#string

Karen Bernard

http://www.w3.org/2001/XMLSchema#string

Na Xie

http://www.w3.org/2001/XMLSchema#string

Rui-Ming Liu

http://www.w3.org/2001/XMLSchema#string

Sami Banerjee

http://www.w3.org/2001/XMLSchema#string

Victor J Thannickal

http://www.w3.org/2001/XMLSchema#string

Zheng Tan

http://www.w3.org/2001/XMLSchema#string

P2860

The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase

Phosphofructokinase 1 glycosylation regulates cell growth and metabolism

Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition

WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis

The myofibroblast: one function, multiple origins

Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery

Recent developments in myofibroblast biology: paradigms for connective tissue remodeling

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

Pulmonary fibrosis: patterns and perpetrators

Myofibroblasts and mechano-regulation of connective tissue remodelling

P304

1462-1474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201504-0780OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

192

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26284610

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

4731722

http://www.w3.org/2001/XMLSchema#string